Anzeige
❌
Mehr »
Donnerstag, 19.11.2026 - Börsentäglich über 12.000 News
Folge dem Geld: Methan im Fokus der COP31!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DLU2 | ISIN: SE0009414576 | Ticker: OND
München
18.11.26 | 08:01
0,160 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ONCOPEPTIDES AB Chart 1 Jahr
5-Tage-Chart
ONCOPEPTIDES AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,1380,17918.11.

Aktuelle News zur ONCOPEPTIDES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09.11.Oncopeptides AB: European Commission approves label expansion of Pepaxti to third-line treatment235STOCKHOLM - November 9, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announced that the European Commission (EC) has formally...
► Artikel lesen
05.11.Oncopeptides AB Q3 Loss Decreases3
05.11.Oncopeptides AB: Oncopeptides publishes Q3 report 2026161Stockholm - November 5, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the third quarter 2026. "Oncopeptides...
► Artikel lesen
09.10.Oncopeptides AB: Oncopeptides confirms blood-brain-barrier penetration based on data from first patients in glioblastoma Window-of-Opportunity study496STOCKHOLM - October 9, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company specializing in difficult-to-treat cancers, today announces data from the first patients in its ongoing...
► Artikel lesen
17.09.Oncopeptides AB: CHMP issues positive opinion of label expansion of Pepaxti to third-line treatment596STOCKHOLM - September 17, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the Committee for Medicinal Products for...
► Artikel lesen
27.08.Oncopeptides Q2 2026 slides: 62% sales growth, 3rd-line expansion6
27.08.Oncopeptides: Umsatz steigt im zweiten Quartal um 62 %, Aktie legt zu4
27.08.Oncopeptides AB Q2 Loss Narrows3
ONCOPEPTIDES Aktie jetzt für 0€ handeln
27.08.Oncopeptides AB: Oncopeptides publishes Q2 report 2026529Stockholm - August 27, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the second quarter 2026. "Oncopeptides...
► Artikel lesen
17.08.Oncopeptides AB: Oncopeptides receives list price for Pepaxti in Slovenia, marking first expansion milestone in Central and Eastern Europe654STOCKHOLM - August 17, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the Public Agency of the Republic of Slovenia...
► Artikel lesen
08.06.Oncopeptides AB: First patient enrolled in Oncopeptides' real-world evidence study MARINA in Germany621STOCKHOLM - June 8, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company specializing in difficult-to-treat cancers, today announces that the first patient has been enrolled in...
► Artikel lesen
26.05.Oncopeptides AB: Oncopeptides signs agreement with Salus for distribution and commercialization of Pepaxti in Central and Eastern Europe545STOCKHOLM, May 26, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that it has entered into an agreement with SALUS,...
► Artikel lesen
21.05.Oncopeptides AB: Bulletin from the Annual General Meeting in Oncopeptides329STOCKHOLM - May 21, 2026 - The Annual General Meeting in Oncopeptides AB (publ) (ONCO) was held on Thursday, 21 May 2026. At the Annual General Meeting, the following principal resolutions were passed. The...
► Artikel lesen
13.05.Oncopeptides AB: Oncopeptides publishes Q1 report 2026746Stockholm - May 13, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the first quarter 2026. "Oncopeptides...
► Artikel lesen
11.05.Oncopeptides AB: Oncopeptides intends to submit type II variation to expand Pepaxti label to include third line treatment381STOCKHOLM - May 11, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces its intention to submit a Type II variation application...
► Artikel lesen
17.03.Oncopeptides AB: Outcome in Oncopeptides' rights issue466THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND...
► Artikel lesen
16.03.Oncopeptides AB: Oncopeptides initiates MARINA study to strengthen real-world evidence for Pepaxti in Germany1.264STOCKHOLM - March 16, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company specializing in difficult-to-treat cancers, today announces the initiation of the MARINA study in close...
► Artikel lesen
09.03.Oncopeptides AB: Oncopeptides secures fast-track designation for Window-of-Opportunity study in glioblastoma619Stockholm, March 9, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company specializing in difficult-to-treat cancers, today announces that it has achieved key regulatory agreement...
► Artikel lesen
24.02.XFRA CAPITAL ADJUSTMENT INFORMATION - 24.02.2026432Das Instrument DEP0 CA24380K4028 DEEPMARKIT CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 24.02.2026 und ex Kapitalmassnahme am 25.02.2026 The instrument DEP0 CA24380K4028 DEEPMARKIT CORP. EQUITY...
► Artikel lesen
19.02.Oncopeptides AB: Oncopeptides publishes year-end report 2025454Stockholm - February 19, 2026 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the year-end report for 2025. "Oncopeptides...
► Artikel lesen
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1